Advertisement

Topics

Adoptive Cell Therapy Following Non-Myeloablate Chemotherapy in Metastatic Melanoma Patients

2014-08-27 03:46:18 | BioPortfolio

Summary

Metastatic melanoma is an aggressive and highly malignant cancer. The five-year survival rate of patients with metastatic disease is less than 5% with a median survival of only 6-10 months. Drugs like Dacarbazin (DTIC) as a single agent or in combination with other chemotherapy agents, have a response rate of 15-30%, but the duration of response is usually short, with no impact on survival. Interleukin-2 (IL-2) based immunotherapy has shown more promising results. This form of therapy has a similar response rate with some patients achieving a durable complete response. Recently the National Institute of Health (NIH) reported that by using lympho-depleting chemotherapy, followed by an adoptive transfer of large numbers of anti-tumor specific tumor-infiltrating lymphocytes (TIL), an objective regression was achieved in 51% of patients with metastatic melanoma.

Objectives: To introduce the TIL technology to advanced metastatic melanoma patients in Israel.

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Metastatic Melanoma

Intervention

Procedure - Adoptive cell transfer

Location

Sheba Medical Center
Tel hashomer
Israel
52621

Status

Recruiting

Source

Sheba Medical Center

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:46:18-0400

Clinical Trials [2672 Associated Clinical Trials listed on BioPortfolio]

Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) in combination with lymphodepletion and high-dose interleukin 2 (IL-2) has demonstrated reproducible objective respon...

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

The overall purpose of this research study is to find a better way to treat melanoma. Although it is the investigators' hope that participants will benefit from taking part in this study, ...

A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients

Considerable progress in the treatment of metastatic melanoma has been made in the past 5years, with the approval of immune checkpoint-blocking antibodies and agents targeting BRAF mutatio...

Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients

To improve the efficacy of immunotherapy for cancer, recent studies focused on specific targets to redirect the immune network toward eradicating a variety of tumors and ameliorating the s...

Cyclophosphamide or Cellular Adoptive Immunotherapy With or Without Aldesleukin in Treating Patients With Metastatic Melanoma

RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bi...

PubMed Articles [22841 Associated PubMed Articles listed on BioPortfolio]

Macrophage Cytoplasmic Transfer in Melanoma Invasion.

Within tumors, macrophage infiltration can promote cancer cell invasiveness and, consequently, metastatic dissemination. In this issue of Developmental Cell, Roh-Johnson et al. (2017) reveal that cyt...

Helping hand for melanoma invasion: transparent zebrafish can catch macrophages in the act.

Coverage on "Macrophage-Dependent Cytoplasmic Transfer during Melanoma Invasion In Vivo" Development Cell, Roh-Johnson et al., 2017, Developmental Cell 43, 549-562.Metastatic melanoma ranks amongst t...

Non-genetic engineering of cytotoxic T cells to target IL-4 receptor enhances tumor homing and therapeutic efficacy against melanoma.

Adoptive transfer of cytotoxic T lymphocytes (CTLs) has been used as an immunotherapy in melanoma. However, the tumor homing and therapeutic efficacy of transferred CTLs against melanoma remain unsati...

A kinetic investigation of interacting, stimulated T cells identifies conditions for rapid functional enhancement, minimal phenotype differentiation, and improved adoptive cell transfer tumor eradication.

For adoptive cell transfer (ACT) immunotherapy of tumor-reactive T cells, an effective therapeutic outcome depends upon cell dose, cell expansion in vivo through a minimally differentiated phenotype, ...

Rare, yet Relevant Tumor Cells - a New Twist to Melanoma Cell Plasticity.

Metastatic cancers, including malignant cutaneous melanoma, have remained an incurable disease for most patients. Major advancements in the fields of targeted therapies and immunotherapies have brough...

Medical and Biotech [MESH] Definitions

Form of passive immunization where previously sensitized immunologic agents (cells or serum) are transferred to non-immune recipients. When transfer of cells is used as a therapy for the treatment of neoplasms, it is called adoptive immunotherapy (IMMUNOTHERAPY, ADOPTIVE).

Separation of one or more kinds of cells from whole blood with the return of other blood cell constituents to the patient or donor. This is accomplished with an instrument that uses centrifugation to separate the cells into different layers based on the differences in cell density (displacement) or drag coefficients in a current (elutriation). The procedure is commonly used in adoptive transfer to isolate NK cells, lymphocytes, or monocytes.

Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER).

An unpigmented malignant melanoma. It is an anaplastic melanoma consisting of cells derived from melanoblasts but not forming melanin. (Dorland, 27th ed; Stedman, 25th ed)

Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)

More From BioPortfolio on "Adoptive Cell Therapy Following Non-Myeloablate Chemotherapy in Metastatic Melanoma Patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Melanoma
Melanoma is a highly malignant tumor of melanin-forming cells (melanocytes) There are most commonly found in the skin (resulting from sunlight exposure), but also in the eyes and mucous membranes. Metastasis to other regions of the body is also common....

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...


Searches Linking to this Trial